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ABSTRACT 
7TMR exists as conformational collections in which different conformations would lead to 
differential downstream behaviors such as receptor phosphorylation, G-protein activation 
and receptor internalization among others. In this context, a ligand may cause differential 
activation of some, but not all, of the signaling events, which are associated to a particular 
receptor, and it would lead to biased agonism. The aim of the present work is to study if 
histamine H2 receptor (H2R) ligands -described as inverse agonists because of their negative 
efficacy at modulating adenylyl cyclase- could display some positive efficacy concerning 
receptor desensitization, internalization or even signaling through an adenylyl cyclase 
independent pathway. Our present findings indicate that treatment with H2R inverse 
agonists leads to receptor internalization in HEK293T transfected cells, by a mechanism 
mediated by arrestin and dynamin but being independent of GRK2-mediated 
phosphorylation. On the other hand we prove that two of the H2R inverse agonists tested, 
ranitidine and tiotidine, also induce receptor desensitization. Finally, we show that these 
ligands are able to display positive efficacy towards ERK1/2 pathway by a mechanism that 
involves GȕȖ and PI3K mediated signaling in both HEK293T transfected cells and human 
gastric adenocarcinoma cells. These results point to the aspect of pluridimensional efficacy 
of H2R as a phenomenon that could be extended to naïve cells, and challenge previous 
classification of pharmacologically relevant histaminergic ligands. 
Summary Statement: In the present work we showed that inverse agonists at histamine H2
receptors display positive efficacy regarding receptor desensitization/internalization and ERK1/2 
phosphorylation. These findings demonstrated that histamine receptor ligands show functional 
selectivity respect to distinct receptor behaviors.
Short title: Pluridimensional efficacy at H2R  
Key words: 7TMR, H2R ligands, biased agonism, pluridimensional efficacy, GPCR 
internalization, MAPK. 
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Abbreviations used: 7TMR, seven transmembrane receptor; H2R, histamine receptor 2; IBMX, 
isobutylmethyl xanthine; MAPK, mitogen-activated protein kinase; BSA, bovine serum albumin; 
HEK293T, human embryonic kidney; AGS, human gastric cancer; cAMP, cyclic AMP; DMEM, 
Dulbecco’s modified Eagle’s medium; GRKs, G protein-coupled receptor kinase; PKA, protein 
kinase A; AC, adenylyl cyclase; EGFR, Epidermal growth factor receptor; GĮt, GĮ transducin; 
PH, pleckstrin homology domain of GRK2; PTX, pertussis toxin. 
INTRODUCTION 
Seven transmembrane receptors (7TMR) represent the largest family of cell surface receptors. 
They mediate signaling across the plasma membrane of a wide variety of stimuli. The canonical 
linear sequence of 7TMR signaling begins when an extracellular stimulus binds and switches the 
receptor from an inactive state to an active state conformation which in turn leads to activation of 
its coupled heterotrimeric G-protein that dissociates from the receptor and both Gα subunit and 
the Gβγ dimer, modulates the activity of an effector enzyme or ion channel. In the classical 
models, signaling by 7TMR is terminated by receptor phosphorylation, principally mediated by 
GRKs; arrestin binding to the phosphorylated receptor which leads to uncoupling from G protein 
and consequent receptor desensitization; and finally internalization by clathrin-coated vesicles 
[1].
Since 7TMR are key regulators of almost every known function of eukaryotic cells, they have 
emerged as the most commonly targeted receptors for human therapeutic. At present they 
represent the target of approximately 27% of all FDA-approved drugs [2, 3]. It is often assumed 
that treatment with agonists leads to tachyphylaxis but 7TMR desensitization is not considered 
when antagonists or inverse agonists are used. This fact mainly results from the traditional 
classification of ligands which considers that 7TMR represent switches that alternate between 
“off” and “on” states. Therefore, agonists and inverse agonists promote an active or inactive state 
of receptors whereas antagonists block the cellular signaling coupled to the receptor. However 
increasing evidence supports that 7TMR exist as conformational collections where each 
conformation promotes different downstream effects such as receptor phosphorylation, G-protein 
activation or receptor internalization among others. In this context, ligand binding stabilizes the 
different conformations through a process known as conformational selection [4]. A consequence 
is biased agonism, where a ligand is able to cause differential activation of some signaling events 
associated to a particular receptor, resulting in differential activation of specific signal 
transduction pathways [5]. This functional selectivity supports that it is the ligand-receptor 
complex which governs the ultimate downstream signaling event and not the receptor itself [6]. 
Therefore it is likely that an antagonist or an inverse agonist stabilizes a particular conformation 
that fails to stimulate a G-protein signaling but results in desensitization, internalization or even 
G-protein independent signaling. Since Galandrin and Bouvier proposed in 2006 this 
pluridimensional characteristic of efficacy, the term efficacy is understood in the context of the 
different behaviors modulated by a 7TMR [7, 8]. Biased agonism has been mainly studied 
regarding adrenergic receptors, but little is known about other ligands therapeutically used [9, 
10]. Cimetidine and ranitidine are clinically employed to control gastric acid secretion and rank 
among the most widely prescribed and over the counter-sold drugs in the world [11, 12]. 
Therefore, in the present study we sought to establish whether H2 receptor ligands widely used 
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and classified as inverse agonists for their negative efficacy in modulating adenylyl cyclase 
display positive efficacy regarding receptor desensitization, internalization or adenylyl cyclase 
independent signaling. 
We show that ranitidine and tiotidine but not cimetidice induced H2R desensitization in 
HEK293T transfected cells mediated by arrestin, clathrin and dynamin leading to receptor down-
regulation. Furthermore, the three inverse agonists induced ERK 1/2 activation not only in 
HEK293T cells but also in human gastric adenocarcinoma cells as histamine and the specific H2R 
agonist, amthamine. 
The present study shows that the H2R ligands classified as inverse agonists display positive 
efficacy regarding receptor desensitization and internalization as well as mitogen-activated 
protein kinases (MAPKs) activation. Our findings may have relevant clinical implications given 
that some of these H2R ligands are clinically used in long-term treatments so they may explain 
therapeutic differences and side effects of histaminergic ligands. 
Experimental Procedures 
Materials. Cell culture medium, antibiotics, isobutylmethyl xanthine (IBMX), cAMP, bovine 
serum albumin (BSA), cycloheximide, amthamine, cimetidine, ranitidine, Tyrphostin AG1478
and pertussis toxin were obtained from Sigma Chemical Company (St. Louis, MO). Tiotidine and 
Ly294002 were from Tocris Cookson Inc. (Ballwin, MO). [3H]cAMP, and [3H]tiotidine were 
purchased from Perkin Elmer Life Sciences (Boston, MA). Fetal calf serum was from Natocor 
(Argentina). Other chemicals used were of analytical grade and obtained from standard sources. 
Plasmid Constructions. pcDNA3-ȕ1arrestin (arrestin 2), pcDNA3-ȕ2arrestin (arrestin 3), 
pcDNA3-HA-dynaminK44A, pcDNA3- ȕ1-arrestin(319–418) and pcDNA3-GRK2-K220R were 
generous gifts from Dr. J. Benovic (Thomas Jefferson University, Microbiology and Immunology 
Department, Kimmel Cancer Center, Philadelphia, PA). pEGFP-C2- Eps15 EH29 construct was a 
generous gift from Dr. Benmerah (Universite´ Paris 5, Institut Cochin, Departement de Maladies 
Infectieuses, Paris, France). GRK2, -3,-5, and -6 cDNAs were subcloned into the pCEFL vector 
(pCEFLGRK2,-3, -5, and -6) as previously described [13]. pCEFLHA-H2R was previously 
generated in our laboratory [13]. pCEFL-GĮ transducin was kindly provided by Dr S. Gutkind 
(Oral and Pharyngeal Cancer Branch, National Institutes of Health, Bethesda). The plasmid 
containing the PH domain of GRK2 was constructed by PCR amplification of bovine GRK2. To 
obtain the PH construct, the sequence coding for residues 553–651 was amplified and inserted 
into EcoRI/Xba site of pCEFL-HA. 
Cell Culture. HEK293T (Human embryonic kidney) and AGS (human gastric cancer) cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) and Kaighn's Modification of Ham's 
F-12 medium (F12K) respectively, supplemented with 10% fetal calf serum and 5 ȝg/ml 
gentamicin at 37°C in humidified atmosphere containing 5% CO2. 
Transient Transfection. For transient transfection of HEK293T, cells were grown to 80-90% 
confluency. cDNA constructs were transfected into cells using LipofectAMINE 2000. The 
transfection protocol was optimized as recommended by the supplier (Invitrogen). Assays were 
performed 48 h after transfection and the expression of the constructs was confirmed by 
immunobloting using specific antibodies. 
cAMP assays. For concentration-response assays, cells were incubated 3 min in basal culture 
medium supplemented with 1 mM IBMX at 37°C, followed by 9 min exposure to different 
concentrations of ligands. 
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For desensitization assays, cells were pretreated with 10 μM H2R ligands in the absence of IBMX 
for different periods of time as shown in the figures. Cells were then washed and resuspended in 
fresh medium containing 1 mM IBMX, incubated for 3 min, and exposed to 10 μM amthamine or 
100 μM histamine for 9 min to determine whether the system was able to generate a cAMP 
response. 
In all experiments, the reaction was stopped by ethanol addition followed by centrifugation at 
2000 x g for 5 min. The ethanol phase was then dried and the residue resuspended in 50 mM 
Tris-HCl pH 7.4, 0.1% BSA. cAMP content was determined by competition of [3H]cAMP for 
PKA, as previously described [14]. 
Radioligand Binding Assay. Saturation binding experiments were carried out by incubating the 
cells for 40 min with increasing concentrations of [3H]tiotidine, ranging from 0.4 up to 240 nM in 
the absence or presence of 1 μM unlabeled tiotidine. The incubation was stopped by dilution with 
3 ml of ice-cold 50 mM Tris-HCl pH 7.4 and the bound fraction was collected in 200 μl of 
ethanol. Experiments on intact cells were carried out at 4°C to avoid ligand internalization. The 
kinetic studies performed with 2 nM [3H]tiotidine at 4°C showed that the equilibrium was 
reached at 30 min and persisted for 4 h (data not shown). 
Receptor internalization and recovery. HEK293T cells were incubated at different times with 10 
μM inverse agonists and the number of receptor sites was analyzed by radioligand binding assay. 
The recovery of binding sites was evaluated by saturation binding assays at 60 min after washing 
the cells previously exposed to 10 μM inverse agonists for 90 min. In assays performed with 50 
ȝM cycloheximide, the inhibitor was added 30 min before ligand treatment.  
Western Blot Assays. For Western blot assays, cells were lysed in 50 mM Tris–HCl pH 6.8, 2% 
SDS, 100 mM 2-mercaptoethanol, 10% glycerol and 0.05% bromophenol blue and sonicated to 
shear DNA. Total cell lysates were resolved by SDS-PAGE, blotted and incubated with the 
primary antibodies anti- dynamin, -GRK2, -GRK3, -GRK5, -GRK6, -ERK1/2, -pERK, -actin 
(Santa Cruz Biotechnology, CA), -arrestin (BD Biosciences PharMingen, San Diego, CA) or -
GFP (Invitrogen), followed by horseradish peroxidase conjugated anti-rabbit or anti-mouse 
(Santa Cruz Biotechnology, CA) and developed by enhanced chemiluminesence (ECL) following 
the manufacturer’s instructions (Amersham Life Science, England). Films were scanned and 
quantified using Scion Image® software from National Institutes of Health (NIH). 
Statistical Analysis. Statistical analysis was performed from at least three independent 
experiments. Binding data, sigmoidal dose-response, desensitization fittings and comparison of 
best fit values according to extra-sum of squares F test were performed with GraphPad Prism 
5.00 for Windows, GraphPad Software (San Diego, CA). One-way ANOVA followed by the 
Dunnett's post-test was performed using GraphPadInStat version 3.01, GraphPad Software (San 
Diego CA). Specific binding was calculated by subtraction of nonspecific binding from total 
binding. Statistical of densitometric western blot analysis were carried out by one-way ANOVA 
or T-test followed by the Dunnett's or Tukey’s Multiple Comparison post-test performed with 
GraphPad Prism 5.00 for Windows, GraphPad Software.  
Results
H2R inverse agonist induced H2R internalization. The effect of cimetidine, ranitidine and 
tiotidine on cAMP accumulation was evaluated in concentration-response assays performed in 
transiently H2R transfected HEK293T cells. As previously reported [15, 16] all ligands inhibited 
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amthanine-induced cAMP accumulation and reduced cAMP levels in a concentration-dependent 
fashion, an effect not blocked by pertussis toxin pretreatment (Fig. 1A, 1B and 1C). These results 
confirm the negative efficacy of the ligands regarding cAMP regulation.   
We next evaluated H2R internalization in HEK293T transfected cells as cell surface receptors 
loss following cimetidine, ranitidine or tiotidine exposure. In saturation binding assays we found 
that despite the absence of positive signaling through Gs-AC-cAMP pathway in the presence of 
the ligands, treatment with ranitidine and tiotidine led to significant H2R internalization (Fig. 
2A). The extent and rate of H2R internalization was similar to amthamine-promoted endocytosis 
(Fig. 2B). On the other hand, cimetidine-treated cells, displayed a considerable slower kinetic 
showing a modest reduction in H2R membrane sites which was significant following 2 h ligand 
exposure (Fig. 2A and B). 
We have previously reported that amthamine treatment evokes H2R internalization into clathrin-
coated vesicles by GRK2 kinase activation as well as arrestin-3, dynamin and Eps15 [17]. In 
order to study the machinery involved in inverse agonists-induced H2R internalization, cells were 
cotransfected with the H2R and dominant negative mutants for arrestin (DNArr), dynamin 
(DNDyn), Eps15 (EH29) or GRK2 kinase inactive (DNGRK2). Saturation binding assays were 
performed after 90 min exposure to ranitidine or tiotidine, given that at this time significant H2R 
internalization was achieved. The proper expression of these constructs in HEK293T 
cotransfected cells was confirmed by western blot (Fig. 3A). 
DNDyn, DNArr or EH29 abolished H2R internalization suggesting that the process is dependent 
on dynamin, arrestin as well as the correct assembly of clathrin-coated vesicles through Eps15. 
Surprisingly, DNGRK2 expression failed to induce ranitidine or tiotidine-evoked H2R 
internalization revealing that GRK2-mediated H2R phosphorylation is not necessary for inverse 
agonist promoted H2R internalization (Fig. 3B). 
Following endocytosis, 7TMR may be either recycled to the plasma membrane or sorted for 
lysosomal degradation. To determine the fate of H2R sites after internalization, we evaluated the 
recovery of membrane H2R sites in the presence or absence of the well-characterized protein 
synthesis inhibitor, cycloheximide. Cells were exposed to ranitidine and tiotidine for 90 min to 
assess H2R sites after cell washing and incubation for 60 min in fresh medium. The removal of 
the stimulus led to a rapid recovery of the number of H2R binding sites that was abolished by 
cycloheximide (Fig. 4). Conversely, cycloheximide treatment did not completely dampen the 
recovery of internalized H2R after amthamine treatment (Fig. 4 inset).  These findings indicate 
that the presence of  H2R sites in the plasma membrane following the  removal of the inverse 
agonists represent  de novo H2R protein synthesis and not H2R recycling [17], suggesting that 
ranitidine and tiotidine induce H2R down-regulation.
H2R inverse agonists induce receptor desensitization. In order to evaluate whether these ligands 
displayed H2R desensitization, H2R transfected HEK293T cells were exposed to 10 μM 
amthamine, cimetidine, ranitidine or tiotidine at different time periods. After carefully washing, 
cells were re-challenged with the agonist and cAMP response was evaluated. The cAMP 
response evoked by amthamine in cells previously exposed to the inverse agonists was 41±7% 
for ranitidine and 36±9% for tiotidine whereas cimetidine did not modify H2R response to the 
agonist. The extent of receptor desensitization appeared to be ligand dependent since amthamine 
induced a 90% H2R desensitization (Fig. 5A). It is worth noting that similar results were obtained 
in response to the endogenous ligand, histamine (Fig. 5B). 
As GRK2 and GRK3 were previously described to mediate H2R homologous desensitization 
[13], we next evaluated whether GRKs were involved in inverse agonists-induced H2R 
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desensitization. For that purpose, HEK293T were co-transfected with the H2R and each of the 
most ubiquitous members of GRK family of proteins (GRK2, 3, 5 and 6). The overexpression of 
GRKs was evaluated by western blot (Fig. 6A) and had no significant effect on inverse agonist-
mediated H2R desensitization (Fig. 6B). Our findings reveal that the GRK family is not involved 
in the mechanism by which H2R lose its ability to respond to amthamine following inverse 
agonist exposure.  
In an attempt to determine whether H2R internalization mediated  inverse agonist-induced H2R 
desensitization, desensitization assays with HEK293T cells cotransfected with a dominant-
negative mutants shown to block H2R endocytosis (Fig. 2B) as well as with wild type arrestin 2 
(Arr2) or arrestin 3 (Arr3) were carried out. Neither dominant negative mutants nor arrestins 
overexpression had a drastic effect on H2R desensitization (Fig. 6C) suggesting that 
internalization is not responsible for inverse agonists-induced H2R desensitization, and ruling out 
uncoupling from G-protein by arrestin.
Modulation of ERK1/2 by H2R inverse agonists. Diverse 7TMR activate MAPK pathways 
through G-protein dependent or independent mechanisms involving Gβγ activity, 7TMR 
internalization, arrestin and/or dynamin recruitment or even EGFR transactivation [18].  
Therefore, we explored whether H2R ligands with negative efficacy at modulating the adenylyl 
cyclase pathway displayed positive efficacy concerning MAPK modulation. As shown in Figure 
7A and B, p-ERK levels were increased by all ligands, being the maximum activation observed at 
5 min following ligand treatment. Given that amthamine and histamine increase cAMP levels and 
cimetidine, ranitidine and tiotidine diminish them (Fig. 7C) these findings show that regardless 
the  efficacy towards the adenylyl cyclase pathway, all ligands displayed positive efficacy respect 
to ERK1/2 modulation, thus behaving as agonists concerning this signaling pathway. 
Arrestin and/or dynamin recruitment by diverse 7TMR leads to MAPK activation [19] so we 
evaluated their role on ERK1/2 modulation. HEK293T cells were co-transfected with H2R and 
DNDyn or DNArr and stimulated with H2R ligands. Results showed that arrestin did not mediate 
ERK1/2 modulation by any of the assayed ligands. On the other hand, only amthamine- induced 
ERK activation mediated by dynamin (Fig. 8A and B). These findings show that although the 
ligands induced ERK activation, the mechanism involved is different from that of amthamine. It 
is worth noting that AG1478, the pharmacological inhibitor of EGFR, had no effect on ERK1/2 
activation by these ligands (data not shown) ruling out the possibility that EGFR transactivation 
might be responsible for ERK1/2 activation as previously described for other 7TMR [20, 21]. 
GȕȖ signaling was previously found to stimulate the PI3K signaling pathway leading to 
downstream activation of ERK1/2 [22]. In order to evaluate the potential implication of GȕȖ in 
MAPK activation by H2R ligands, ERK1/2 modulation was evaluated in HEK293T cells co-
transfected with H2R and GĮ transducin (Gαt), a widely used scavenger of GȕȖ [23, 24]. In the 
presence of GĮt, cimetidine, ranitidine and tiotidine-induced ERK1/2 phosphorylation was 
significantly inhibited (Fig. 9A). These results were confirmed by the pleckstrin homology (PH) 
domain of GRK2, another well described scavenger of GȕȖ [25, 26] (Fig. 9B). Moreover, 
Ly294002 inhibitor of PI3K, also blocked cimetidine, ranitidine and tiotidine induced ERK1/2 
phosphorylation (Fig. 9C). In addition, the increase in p-ERK levels following amthamine 
treatment was not dampened by Gαt, confirming the central role of dynamin on amthamine 
induced ERK1/2 activation (Fig. 9D). Overall, these results show that ligands previously 
described as H2R inverse agonists regarding the Gs-AC-cAMP pathway display positive efficacy 
towards ERK1/2 through a pathway involving the GȕȖ dimer and PI3K activation.  
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cAMP accumulation and MAPK activation by H2R ligands in human gastric adenocarcinoma 
AGS cells. AGS cells not only endogenously express H2R but also represent a relevant model 
concerning H2R histaminergic ligands and their clinical use. Regarding cAMP accumulation 
histamine and amthamine displayed positive efficacy while cimetidine, ranitidine and tiotidine 
did not significantly reduced cAMP basal levels (Fig. 10A). Although constitutive activity of 
H2R was consistently reported, its modulation is difficult to achieve on naïve systems [15]. 
Interestingly, positive efficacy of cimetidine, ranitidine and tiotidine, towards ERK1/2 
modulation was also found in AGS cells where the highest response was observed at 10 min. 
(Fig. 10). Moreover, cimetidine-induced phosphorylation of ERK1/2 was similar to that 
stimulated by amthamine (Fig. 10B and C). These findings clearly show that histamine H2R 
ligands classically classified as antagonist or inverse agonists based on cAMP modulation may 
induce ERK1/2 phosphorylation through an adenylyl cyclase independent pathway not only in 
overexpression models but also in human gastric adenocarcinoma cells that endogenously 
express H2R. 
Discussion 
In the context of pluridimensional efficacy where receptors exhibit diverse behaviors and ligands 
display different efficacies depending on the readout chosen as receptor response, the major 
finding of our work was the identification of different efficacies displayed by H2R ligands 
towards receptor desensitization/internalization, GĮs-AC, and GȕȖ-ERK1/2 pathways. 
Histamine H2 receptor ligands were traditionally classified according to their ability to modulate 
cAMP levels. Thus, cimetidine, ranitidine and tiotidine were originally considered neutral 
antagonists, but when receptor constitutive activity became evident they were reclassified as 
inverse agonists, with negative efficacy [15, 16]. However, the diversity of effectors considered 
in this work, challenged this simple scheme, making it difficult to categorize these ligands 
according to unique efficacy terms.  
In the present work we show that not only amthamine, but also ranitidine and tiotidine induced 
significant receptor desensitization and internalization (Fig. 2 and 3). It is worth noting that 
attenuation mechanisms of 7TMR signaling have been originally described as adaptive processes 
evoked by agonists to prevent receptor overstimulation, but despite the lack of positive cAMP 
response evoked by these ligands, they induced substantial internalization and desensitization of 
H2R.  
Receptor desensitization triggered by ranitidine and tiotidine was independent of arrestin-2, -3 
and the GRKs, whereas receptor internalization was mediated by arrestin, dynamin, and clathrin, 
but not by GRK2 phosphorylation. Moreover, inverse agonist-induced H2R internalization 
appeared to mediate receptor down-regulation rather than recycling, as previously observed for 
the agonist amthamine [17]. These findings support that inverse agonist induced receptor 
desensitization/internalization protein-partners profile and cellular fate once the receptor is 
internalized, is strikingly different from that observed when the processes are triggered by 
agonists. Although ligand efficacies are shared, the mechanisms involved differ, supporting that 
the receptor partners engaged in a certain pathway are strongly dependent on the ligand. 
Futhermore an additional level of selectivity was revealed when the signaling cascades leading to 
ERK1/2 activation were examined. Again, although all ligands evaluated displayed positive 
efficacy concerning ERK1/2 phosphorylation, the underlying mechanisms differed. Amthamine- 
stimulated ERK1/2 phosphorylation was mediated by dynamin (Fig. 8), as previously described 
for dimaprit, another H2R agonist [27], while cimetidine, ranitidine and tiotidine led to an 
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increase in pERK levels by a mechanism independent of dynamin, arrestin, H2R internalization or 
even EGFR transactivation, but mediated by GȕȖ.  
Intriguingly, tiotidine, ranitidine, and cimetidine seemed to inactivate GĮs, diminishing cAMP 
levels, but stimulating GȕȖ dependent pERK pathway. Considering the paradigm of 
heterotrimeric G protein activation, an apparent discrepancy in the activation of the GȕȖ dimer 
seems to exist while the GĮs subunit remains inactive. However, the way in which G proteins are 
activated and propagate the signal has been challenged. Originally, GĮ was thought to be the only 
G protein subunit able to govern the direct interaction with effector molecules but GȕȖ has signal 
transduction properties of its own [28]. Therefore, subunit dissociation produces two signal 
transduction molecules when heterotrimeric G proteins are activated. However, the mechanism 
by which divergent signaling pathways within the cell are controlled by an unique receptor 
remains controversial. Thus, subunit dissociation is a critical event of the signal transduction 
mechanisms and it is essential that the subunit dissociation hypothesis be unequivocally 
established. Although this hypothesis is generally accepted [29, 30], there is evidence supporting 
that G protein activation occurs without dissociation and that subunit dissociation occurs without 
activation [31]. Our findings support that G protein heterotrimer do not need to be fully activated 
and that GȕȖ pathway activation do not necessarily implies GĮs activity. 
Overall, these results indicate that different ligands can lead to recruitment of distinct subsets of 
signaling effectors to activate a single pathway. This is reminiscent of other cases where distinct 
effectors were selectively engaged by different ligand/receptor pairs to stimulate a common 
downstream signaling integrator [32]. 
Nowadays 7TMRs are thought as allosteric machines where a punctual modification in the free 
energy of the receptor is transmitted to the rest of the protein affecting the receptor response to 
the cytosolic signaling proteins. Molecular dynamic modeling of proteins predicts that numerous 
protein conformations can exist and that receptors exist in “ensembles” of multiple conformations 
[33, 34]. Under these circumstances, ligand binding alters the receptor ensemble formation, 
causing the stabilization of different receptor conformations with different properties and 
behaviors. The machinery involved in inverse agonist stimulated-internalization was independent 
of GRK2-induced phosphorylation.Therefore ranitidine and tiotidine may induce or stabilize a 
conformation that exposes a receptor domain which recruits arrestin and the machinery involved 
in H2R internalization. In consequence, GRK2 phosphorylation may not be necessary to induce 
inverse agonist-mediated H2R internalization. This idea suggests that the conformation induced 
by the H2R inverse agonist is similar to that induced by GRK2 mediated-phosphorylation. Similar 
results concerning phophorylation independent antagonist-stimulated endocytosis of GPCRs were 
previously reported for cholecystokinin receptor [35]. Moreover, Haribabu and coworkers [36] 
reported that a carboxyl-terminal truncation mutant of human chemokine receptors CXCR4 could 
also internalize upon agonist challenge, although this mutant receptor showed no 
phosphorylation. In addition, Zhang X and coworkers [37] demonstrated that agonist-stimulated į
opioid receptor (DOR) internalization includes both receptor phosphorylation-dependent and 
phosphorylation-independent mechanisms and both were mediated by clathrin and ȕ-arrestins. 
The H2R ligands tested in the present study displayed distinct efficacy profiles towards adenylyl 
cyclase and MAPKs, demonstrating the existence of functional selectivity of H2R ligands. 
Whereas amthamine behaves as full agonist concerning both adenylyl cyclase and MAPK 
signaling, cimetidine, ranitidine and tiotidine displayed negative and positive efficacy for these 
pathways. Our results show that while amthamine-induced receptor conformation triggers the 
classical pathways involving GĮs activation and GRK2-ȕarrestin-dynamin-clathrin recruitment 
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for receptor desensitization/internalization leading to ERK1/2 activation and receptor recycling to 
cell membrane, ranitidine and tiotidine may stabilize a conformation that exposes a receptor 
domain which activates GȕȖ-ERK1/2 pathway, recruits arrestin and the the machinery involved 
in H2R desensitization and internalization without GRK2 phosphorylation and changing the 
receptor fate from recycling to degradation. Conversely, cimetidine induced a conformation 
engaged in GȕȖ-ERK1/2 activation but not in receptor desensitization/ internalization. Overall, 
our results show that efficacy is not linear (i.e., ligands do not facilitate all behaviors of receptors) 
but rather is collateral, whereby only a subset of receptor behaviors can be activated or even 
inactivated. There are many possible receptor-based efficacies, and ligands may have varying 
subsets of efficacies. Similarly, it has been previously shown that ȕ2-adrenergic, V2-vasopressin, 
serotonin 5-HT2C, and į-opioid receptor ligands can act as inverse agonists on the adenylyl 
cyclase pathway but as agonists for MAPK signaling [38-41]. 
The observations made in AGS cells, that endogenously express H2R, suggest that the 
pluridimensionality of signaling efficacies may be extended to naïve cells making our findings 
pharmacologically relevant. Recent data provide evidence of the existence of ligand-specific H2R 
conformations that explain the differences among these ligands’ affinities, potencies and 
efficacies observed in neutrophils and eosinophils [42]. Nevertheless, additional studies are 
needed to assess the extent to which the effector-dependent signaling efficacies are detected in 
normal and pathophysiological conditions. 
Since cimetidine and ranitidine profiles as biased ligands were described in in-vitro studies; the 
therapeutic impact of this phenomenon in-vivo cannot be inferred. These ligands are currently 
marketed and used to treat duodenal ulcers and prevent their recurrence. They are also used to 
treat gastric ulcers and Zollinger-Ellison disease [43]. However, these ligands are used because 
they inhibit H2R coupled cAMP response, but while both induce ERK activation like histamine, 
only ranitidine promotes the depletion of receptors from the membrane surface. Therefore the 
outcome of a long term treatment with these ligands would not be alike. 
Although the signaling bias shown in this work runs counter to classic concepts of ligand 
efficacy, those aspects of drug receptor mechanisms has become firmly established and has been 
demonstrated for many receptors [44]. In the same way, present findings stress the relevance of 
studying the different efficacies of a ligand that appears to induce an inactive state of the 
receptor, further if accurate evaluation and understanding of its pharmacological behavior is 
intended. 
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Figure 1. Negative efficacy of cimetidine, ranitidine and tiotidine. (A) H2R transfected 
HEK293T cells were exposed to 10 μM amthamine alone or in combination with inverse agonists 
for 9 min, in the presence of IBMX. ** p<0.01 with respect to amthamine; ## p <0.01 with respect 
to basal. (B) Cells were exposed for 9 min to increasing concentrations of cimetidine (Ɣ), 
ranitidine (Ŷ) or tiotidine (Ÿ) at 37°C in the presence of 1 mM IBMX. (C) Cells were pretreated 
for 6 h with (black bars) or  without (white open bars) 100 ng/ml pertussis toxin and exposed to 
10 ȝM  specific ligand for 9 min, in the presence of IBMX. *** p<0.001 with respect to basal; ns,
with respect to the same treatment without pertussis toxin. (A-C) Cyclic AMP levels were 
determined as detailed under Experimental Procedures. Data were calculated as the means ± SD 
of assay duplicates. Similar results were obtained in at least three independent experiments. 
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Figure 2. Inverse agonists induced H2R internalization. (A) H2R-transfected HEK293T cells 
were exposed to 10 μM cimetidine (Ɣ), ranitidine (Ŷ), tiotidine (Ÿ) or amthamine (ż) for 
different time periods and H2R binding sites were determined by saturation assays as described 
under Experimental Procedures. Data were calculated as the means ± SD of assay duplicates. 
Similar results were obtained in at least three independent experiments. ** p<0.01; *** p<0.001 
with respect to 100%. (B) Half-life constants of the internalization kinetics were derived by curve 
fitting of experiments in A, the data represent the means ± SE (n=3). 
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Figure 3. Mechanisms involved in H2R inverse agonists- induced internalization. HEK293T 
cells were co-transfected with H2R and Arrestin 319-418 (DNArr), Dynamin K44A (DNDyn), 
EH29 or GRK2K220R (DNGRK2) dominant negative constructs. (A), analysis of constructs 
expression in HEK293T-transfected cells. Cells were lysed, and equal amounts of proteins were 
subjected to SDS-PAGE and analyzed by Western Blot using: upper panel left, anti-arrestin 2/3 
antibody; upper panel right, anti-dynamin antibody; down panel left, anti-GFP antibody; down 
panel right, anti-GRK2 antibody. Data are representative of at least three independent 
experiments. (B), Transfected cells were treated for 90 min with 10 μM ranitidine (grey bars) or 
10 μM tiotidine (black bars) and H2R membrane sites are shown. Data represent % Bmax fitted 
by nonlinear regression of [3H]Tiotidine saturation assay, expressed as the means ± SE (n=3). 
100% corresponds to transfected cells without treatment (white bars). ** p<0.01 with respect to 
untreated cells. 
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Figure 4. H2R internalization and recovery in the presence of cycloheximide. [3H]Tiotidine 
saturation assays were performed in H2R-transfected HEK293T cells treated for 90 min with 10 
μM ranitidine (Ŷ) or 10 μM tiotidine (Ÿ), washed (↓), and further incubated for 60 min in fresh 
medium. Open symbols represent the same treatment in the presence of 50 μM cycloheximide. 
Data represent the percentage Bmax value fitted by nonlinear regression of [3H]Tiotidine 
saturation assay, calculated as the means ± SE (n = 3). ** p<0.01 vs.  similar assay in the absence 
of cycloheximide; 100% correspond to untreated cells. Inset. H2R-transfected HEK293T cells 
were treated for 90 min with 10 μM amthamine (90), washed and further incubated for 60 min in 
fresh medium (150). Assays were carried out in the absence (black bars) or presence of 
cycloheximide (white bars) and results were expressed as mentioned above, no significant 
differences are observed between cycloheximide treated or untreated cells (ns). 
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Figure 5. Inverse agonists promoted desensitization. (A), H2R-transfected HEK293T cells were 
exposed to 10 μM cimetidine (Ɣ), ranitidine (Ŷ), tiotidine (Ÿ) or amthamine (ż) for different 
time periods and cAMP response to amthamine was determined. (B), cells pre-treated for 10 min 
with 10 μM amthamine (Amtha), cimetidine (Cim), ranitidine (Ran) or tiotidine (Tio) were 
washed and exposed for 9 min to 100 μM histamine in the presence of IBMX. Cyclic AMP levels 
were determined as detailed under Experimental Procedures and expressed as stimulus to the 
agonist minus basal cAMP levels respect to the response of control cells without treatment. Data 
were calculated as the means ± SD of assay triplicates. Similar results were obtained in at least 
four independent experiments. ** p<0.01 with respect to untreated cells. 
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Figure 6. Characterization of H2R desensitization promoted by inverse agonists. (A), analysis 
of GRKs expression in HEK293T-transfected cells. Cells were lysed, and equal amounts of 
proteins were subjected to SDS-PAGE and analyzed by Western Blot using specific antibodies 
against GRK2, 3, 5 or 6 (from left to right). (B) HEK293T cells transfected with H2R or co-
transfected with different GRKs, were pre-treated for 10 min with 10 µM cimetidine (slashed 
bars), ranitidine (grey bars) or tiotidine (black bars), (C) cells transfected with H2R or co-
transfected with dominant negative dynamine (DNDyn) and arrestin (DNArr) mutants or wild 
type arrestins were pre-treated for 10 min with 10 µM ranitidine (grey bars) or tiotidine (black 
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bars). Cells were washed and exposed for 9 min to 10 μM amthamine in the presence of IBMX. 
Cyclic AMP levels were determined as detailed under Experimental Procedures and expressed as 
stimulus to the agonist minus basal cAMP levels respect to the response to amthamine of cells 
without treatment (white bars). Data were calculated as the means ± SD of assay triplicates. 
Similar results were obtained in three independent experiments. ** p<0.01 with respect to 
untreated cells. 
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Figure 7. ERK phosphorylation in response to H2R ligands. (A), H2R transfected HEK293T 
cells were treated during different time periods, lysed, and equal amounts of proteins were 
subjected to SDS-PAGE and analyzed by Western Blot. (B), Densitometric analysis of ERK 
phosphorylation at 5 min of treatment, normalized to the corresponding ERK total levels, 
obtained with the Scion Image Program. Data are expressed as times over basal p-ERK levels. 
Data are expressed as means ± SE (n=3). ** p<0.01; *** p<0.001 respect to basal levels. (C), 
cAMP kinetics following exposure to10 μM cimetidine (Cim) (Ɣ), ranitidine (Ran) (Ŷ), tiotidine 
(Tio) (Ÿ), or amthamine (Amtha) (ż). 
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Figure 8. Characterization of inverse agonists mediated ERK phosphorylation. (A), HEK293T 
cells transfected with H2R or co-transfected with Arrestin 319-418 (DNArr) or Dynamin K44A 
(DNDyn) dominant negative constructs were treated during different time periods with 10 μM 
cimetidine (Cim), ranitidine (Ran) or tiotidine (Tio), lysed, and equal amounts of proteins were 
subjected to SDS-PAGE and analyzed by Western Blot. (B), Densitometric analysis of ERK 
phosphorylation at 5 min of treatment in control (white bars) co-transfected with Arrestin 319-
418 (grey bars) or Dynamin K44A (black bars), normalized to the corresponding ERK total 
levels, obtained with the Scion Image Program. Data are expressed as times over basal p-ERK 
levels. Data are expressed as means ± SE (n=3); *** p<0.001 respect to basal levels.
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Figure 9. GȕȖ involvement in inverse agonists mediated ERK phosphorylation. (A), HEK293T 
cells transfected with H2R or cotransfected with GĮ transducin (GT) (B), or the PH domain 
(pleckstrin homology domain of GRK2) constructs (C) or pretreated for 30 min with 10 μM 
Ly294002 were treated during different time periods with 10 μM cimetidine (Cim), ranitidine 
(Ran) or tiotidine (Tio),  lysed, and equal amounts of proteins were subjected to SDS-PAGE and 
analyzed by Western Blot. (D) HEK293T cells transfected with H2R or cotransfected with 
GĮtransducin (GT), were treated for 5 min with 10 μM amthamine, lysed, and equal amounts of 
proteins were subjected to SDS-PAGE and analyzed by Western Blot. Right panels, 
Densitometric analysis of ERK phosphorylation at 5 min of treatment in control (white bars) co-
transfected with PH, GtĮ or pretreated with Ly294002 (black bars), normalized to the 
corresponding ERK total levels, obtained with the Scion Image Program. Data are expressed as 
times over basal p-ERK levels. Data are expressed as means ± SE (n=3).* p<0.05; ** p<0.01; 
*** p<0.001. 
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Figure 10. Biased inverse agonism in human gastric AGS cells. (A) AGS cells were treated 
during 9 min with 100 μM histamine (Hist) or 10 μM amthamine (Amtha), cimetidine (Cim), 
ranitidine (Ran) or tiotidine (Tio) in presence of IBMX. Cyclic AMP levels were determined as 
detailed under Experimental Procedures. Data were calculated as the means ± SD of assay 
duplicates. (B), AGS cells were treated during different time periods with 100 μM histamine 
(Hist) or 10 μM amthamine (Amtha), cimetidine (Cim), ranitidine (Ran) or tiotidine (Tio), lysed, 
and equal amounts of proteins were subjected to SDS-PAGE and analyzed by Western Blot. (C),
Densitometric analysis of ERK phosphorylation at 5 min of treatment, normalized to the 
corresponding ERK total levels, obtained with the Scion Image Program. Data are expressed as 
times over basal p-ERK levels. Data are expressed as means ± SE (n=3). * p<0.05; ** p<0.01; 
*** p<0.001 respect to basal levels. 
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